1.

Early Experience of Pirfenidone in Daily Clinical Practice in Belgium and The Netherlands: a Retrospective Cohort Analysis

2.

Early Experience of Pirfenidone in Daily Clinical Practice in Belgium and The Netherlands: a Retrospective Cohort Analysis

3.

Early Experience of Pirfenidone in Daily Clinical Practice in Belgium and The Netherlands: a Retrospective Cohort Analysis

4.

Early Experience of Pirfenidone in Daily Clinical Practice in Belgium and The Netherlands: a Retrospective Cohort Analysis

5.

Early Experience of Pirfenidone in Daily Clinical Practice in Belgium and The Netherlands: a Retrospective Cohort Analysis

6.

Early Experience of Pirfenidone in Daily Clinical Practice in Belgium and The Netherlands: a Retrospective Cohort Analysis

7.

Early Experience of Pirfenidone in Daily Clinical Practice in Belgium and The Netherlands: a Retrospective Cohort Analysis

1.

High incidence of the CFTR mutations 3272-26A -> G and L927P in Belgian cystic fibrosis patients, and identification of three new CFTR mutations (l86-2A -> G, E588V, and 1671...

1.

Correlation of BAL Cell Count and Pulmonary Function Tests in the Era of Antifibrotics: Data From the Belgium-Luxembourg Idiopathic Pulmonary Fibrosis Registry.

2.

Correlation of BAL Cell Count and Pulmonary Function Tests in the Era of Antifibrotics: Data From the Belgium-Luxembourg Idiopathic Pulmonary Fibrosis Registry.

3.

Correlation of BAL Cell Count and Pulmonary Function Tests in the Era of Antifibrotics: Data From the Belgium-Luxembourg Idiopathic Pulmonary Fibrosis Registry.

4.

Correlation of BAL Cell Count and Pulmonary Function Tests in the Era of Antifibrotics: Data From the Belgium-Luxembourg Idiopathic Pulmonary Fibrosis Registry.

5.

Correlation of BAL Cell Count and Pulmonary Function Tests in the Era of Antifibrotics: Data From the Belgium-Luxembourg Idiopathic Pulmonary Fibrosis Registry.

6.

Correlation of BAL Cell Count and Pulmonary Function Tests in the Era of Antifibrotics: Data From the Belgium-Luxembourg Idiopathic Pulmonary Fibrosis Registry.

7.

Correlation of BAL Cell Count and Pulmonary Function Tests in the Era of Antifibrotics: Data From the Belgium-Luxembourg Idiopathic Pulmonary Fibrosis Registry.

8.

Correlation of BAL Cell Count and Pulmonary Function Tests in the Era of Antifibrotics: Data From the Belgium-Luxembourg Idiopathic Pulmonary Fibrosis Registry.

9.

Correlation of BAL Cell Count and Pulmonary Function Tests in the Era of Antifibrotics: Data From the Belgium-Luxembourg Idiopathic Pulmonary Fibrosis Registry.

1.

Correlation of Broncho-Alveolar Lavage Cell Count and Pulmonary Function Tests in the Era of Antifibrotics: Data from the Belgium-Luxembourg IPF registry

2.

Correlation of Broncho-Alveolar Lavage Cell Count and Pulmonary Function Tests in the Era of Antifibrotics: Data from the Belgium-Luxembourg IPF registry

3.

Correlation of Broncho-Alveolar Lavage Cell Count and Pulmonary Function Tests in the Era of Antifibrotics: Data from the Belgium-Luxembourg IPF registry

1.

Correlation of Broncho-Alveolar Lavage Cell Count and Pulmonary Function Tests in the Era of Antifibrotics: Data from the Belgium-Luxembourg IPF registry.

2.

Correlation of Broncho-Alveolar Lavage Cell Count and Pulmonary Function Tests in the Era of Antifibrotics: Data from the Belgium-Luxembourg IPF registry.

3.

Correlation of Broncho-Alveolar Lavage Cell Count and Pulmonary Function Tests in the Era of Antifibrotics: Data from the Belgium-Luxembourg IPF registry.

4.

Correlation of Broncho-Alveolar Lavage Cell Count and Pulmonary Function Tests in the Era of Antifibrotics: Data from the Belgium-Luxembourg IPF registry.

5.

Correlation of Broncho-Alveolar Lavage Cell Count and Pulmonary Function Tests in the Era of Antifibrotics: Data from the Belgium-Luxembourg IPF registry.

6.

Correlation of Broncho-Alveolar Lavage Cell Count and Pulmonary Function Tests in the Era of Antifibrotics: Data from the Belgium-Luxembourg IPF registry.

7.

Correlation of Broncho-Alveolar Lavage Cell Count and Pulmonary Function Tests in the Era of Antifibrotics: Data from the Belgium-Luxembourg IPF registry.

1.

High incidence of the CFTR mutations 3272-26A G and L927P in Belgian cystic fibrosis patients, and identification of three new CFTR mutations (186-2A G, E588V, and 1671insTATATCA)

1.

High incidence of the CFTR mutations 3272-26A→G and L927P in Belgian cystic fibrosis patients, and identification of three new CFTR mutations (186-2A→G, E588V, and 1671insTATCA)...

1.

Erratum to “High incidence of the CFTR mutations 3272-26A → G and L927P in Belgian cystic fibrosis patients, and identification of three new CFTR mutations (186-2A → G, E588V, and...

1.

Incidence, prevalence and long-term progression of Goh algorithm rated interstitial lung disease in systemic sclerosis in two independent cohorts in flanders: A retrospective cohor...

1.

Incidence, prevalence and long-term progression of Goh algorithm rated interstitial lung disease in systemic sclerosis in two independent cohorts in flanders : a retrospective coho...